Blythe Sather

International Therapeutics (United States)

Also affiliated with Juno Therapeutics (Germany), Bristol-Myers Squibb (Belgium)

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial”.

γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial

The Lancet Oncology(2023)10.1016/s1470-2045(23)00246-2

N/A

2.5DataRank · unranked

101 citations

Margot J. Pont, Blythe Sather, Cameron J. Turtle, Brian G. Till, Edward N. Libby +15 more

Effective, safe, and sustained correction of murine XLA using a UCOE-BTK promoter-based lentiviral vector

Molecular Therapy — Methods & Clinical Development(2021)10.1016/j.omtm.2021.01.007

N/A

0DataRank · unranked

18 citations

Swati Singh, Hannah M. Certo, Karen Sommer, Blythe Sather, Socheath Khim +8 more